Fast-Dispersing Riluzole Tablets to Bypass First-Pass Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Riluzole tablets have pharmacokinetic and pharmaceutic limitations such as high first-pass metabolism, low bioavailability, and dose-dependent liver function issues, making them challenging for patients with swallowing difficulties and increasing the risk of hepatic enzyme elevations.
Innovation Solution
Development of a fast-dispersing oral solid dosage form of riluzole tablets that provides an AUC0-t of 80-125% of conventional tablets, with a dosage of 50-90% of conventional tablets, formulated with riluzole, fish gelatin, mannitol, and a flavorant, to enhance absorption and reduce liver metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional riluzole tablets are used, then the drug provides therapeutic effect for ALS, but it causes high first-pass metabolism and low bioavailability
Solution Approach 1:
The patent introduces a sublingual administration route as an intermediary pathway between oral intake and systemic circulation. By placing the tablet under the tongue, the drug bypasses the hepatic first-pass metabolism through the rich vascular network of the sublingual mucosa, directly entering the bloodstream. This mediator approach resolves the contradiction by providing a alternative route that maintains therapeutic effect while reducing first-pass metabolism losses.
Solution Approach 2:
The patent changes the administration parameter from conventional oral swallowing to sublingual placement. This parameter change fundamentally alters the pharmacokinetic pathway, transforming the drug's journey from gastrointestinal absorption through liver metabolism to direct sublingual absorption. The change in administration method resolves the bioavailability issue by eliminating the problematic first-pass metabolism step.
2Reliability
If conventional riluzole tablets are used, then the drug is effective for ALS treatment, but it causes dose-dependent liver function issues
Solution Approach 1:
The sublingual route acts as a protective intermediary that shields the liver from direct drug exposure during the first-pass metabolism. By bypassing the hepatic portal circulation, the drug avoids the dose-dependent metabolic processing that causes liver enzyme elevations and function issues, while still achieving effective systemic concentrations for ALS treatment.
Solution Approach 2:
The patent converts the harmful effect of extensive liver metabolism into a benefit by utilizing the sublingual vascular network's direct connection to the systemic circulation. This transformation eliminates the harmful first-pass metabolism while maintaining therapeutic effectiveness, turning a previously problematic pathway into an advantageous one.
3Reliability
If conventional riluzole tablets are used, then the drug achieves therapeutic concentrations, but it has low bioavailability and requires high dosing
Solution Approach 1:
The patent changes the absorption parameter by utilizing the sublingual mucosa's rich vascular supply, which provides direct access to the systemic circulation. This parameter change in the administration route fundamentally improves bioavailability, allowing lower dosages to achieve the same therapeutic concentrations that previously required higher doses through conventional oral tablets.
Solution Approach 2:
The sublingual route serves as an efficient intermediary that directly delivers drug to the bloodstream, eliminating the lossy intermediate steps of gastrointestinal absorption and hepatic first-pass metabolism. This intermediary pathway increases the fraction of drug reaching systemic circulation, thereby reducing the required dosage amount while maintaining therapeutic concentrations.
4Reliability
If conventional riluzole tablets are used, then the drug provides treatment, but it causes swallowing difficulties for patients with ALS
Solution Approach 1:
The patent segments the administration process into two distinct phases: (1) placement of the tablet under the tongue, and (2) automatic dissolution and absorption through the sublingual mucosa. This segmentation eliminates the swallowing action entirely, as the tablet is placed rather than swallowed, thereby resolving the contradiction between providing treatment and avoiding swallowing difficulties in ALS patients.
Solution Approach 2:
The tablet is designed to automatically dissolve and release its contents through the sublingual environment without requiring active swallowing or chewing by the patient. The formulation itself performs the dissolution function, making the treatment process easier to operate for patients with compromised swallowing abilities while maintaining effective treatment provision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fast-dispersing tablets improve bioavailability and reduce liver metabolism risks, offering a more effective and safer administration option for patients, including those with ALS and other conditions.
Implementation Method 1
fast-dispersing oral solid dosage form of riluzole tablets that provides an AUC0-t of 80-125% of conventional tablets
Implementation Method 2
high first-pass metabolism, low bioavailability, and dose-dependent liver function issues
Data Source
AI summary
Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof, in the form of an oral solid molded fast-dispersing dosage form. Pharmaceutical compositions and kits are also disclosed.